6505--Radiopharmaceuticals for Positron Emitting Tomography (PET) Imaging
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office 19, has awarded a contract for Radiopharmaceuticals for Positron Emitting Tomography (PET) Imaging to PHARMALOGIC HOLDINGS CORP. This award, valued at $541,308.00, was made on April 8, 2026, under a Total Small Business Set-Aside.
Scope of Work
The contract requires the provision of unit dose radiopharmaceuticals, radioactive sources, and supplies for diagnostic imaging exams and quality assurance procedures at the VA Salt Lake City Health Care System (VASLCHCS). Key deliverables include:
- Routine weekday deliveries of F-18 Piflufolastat (Pylarify), or equivalent, for PET imaging by 8:00 AM MST.
- Provision of radioactive sources for quality assurance/quality control.
- Preparation of radiopharmaceuticals according to manufacturer's inserts by certified nuclear medicine pharmacists.
- Supply of radiation safety equipment (syringe shields, shielded carriers).
- Maintenance of adequate supply chain with contingency plans.
- Urgent delivery capability within two hours during normal working hours.
- Compliance with U.S. Pharmacopeia (USP) 797 and 825 guidelines, and all federal/state regulations for shipping radioactive materials.
- Contractor must be licensed by the State of Utah and hold current NRC and/or FDA licenses.
- Acceptance of returns for credit under specified conditions.
- Provision of technical expertise and quality control statements.
Contract Details
- Awardee: PHARMALOGIC HOLDINGS CORP.
- Award Number: 36C25926P0374
- Award Date: April 8, 2026
- Award Amount: $541,308.00
- Contract Type: Firm-Fixed-Price (as per original solicitation)
- Period of Performance: The original solicitation and price schedule indicated a base year (April 1, 2026 – March 31, 2027) plus three option years, with a total contract duration not exceeding 3 years (FAR 52.217-9) and potential for extension up to 6 months (FAR 52.217-8). The Q&A clarified the intent for a 4-year contract, funded annually.
- Set-Aside: Total Small Business Set-Aside (FAR 19.5)
- Product Service Code: 6505 (Drugs And Biologicals)
Place of Performance
Deliveries are to the Nuclear Medicine Department, VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148.
Original Solicitation & Evaluation
The original solicitation (RFQ #: 36C25926Q0316) was a 100% Small Business set-aside. Evaluation factors included technical capability/quality, price, and required licenses (Utah Professional, NRC/FDA, Radioactive Material), and completion of the Buy American Certificate. Award was to be made on an "All or Nothing Basis."
Contact Information
For inquiries, the primary contact is Heather Chase at heather.chase2@va.gov or 303-712-5772.